The two main objectives of the study are to investigate the ability of Vacc-4x to improve the CD4 T-cell count in patients who have failed to regain these T helper cell counts to nearly normal ...

The HIV viral load set point in patients given Vacc-4x was 60% lower than pre-ART (level before starting with standard medicine, ART). In the placebo group, no change compared to pre-ART was observed.

Participants with anti-C5/gp41732-744 antibody levels below 4μg/ml who received Vacc-4x had a median viral load reduction of log 0.20 or 37% (p=0.019, n=27) compared to their median pre-ART viral ...

Vacc-4x is a therapeutic HIV-vaccine based on four, slightly modified peptides (building blocks of proteins) from conserved parts of the HIV-virus. Endocine is an adjuvant shown to enhance the ...

Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo - Bionor Pharma reverses decision to put Vacc-4x on hold After further analyses ...

Bionor Pharma ASA (OSLO: BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the "Boost & Kill" study. The Phase II trial was an exploratory double-blind ...

July 26, 2011 (Rome, Italy) — Vacc-4x, a peptide-based therapeutic vaccine, appears to reduce the viral load in patients with HIV who have maintained a viral response after discontinuing ...

OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 ...

The study was designed to test HIV-patients' ability to stay off anti-retroviral therapy (ART) after having been immunized with Vacc-4x. Although the study did not meet its primary endpoints, as ...

Data from Vacc-4x study presented at largest and most prestigious global scientific conference focused exclusively on AIDS vaccine research The comprehensive analysis of the Vacc-4x phase II study ...

supports that the combination of Vacc-4x and the latency reversing agent romidepsin (Istodax, Celgene) leads to a reduction in latent viral reservoir Sign up here. * Expects to initiate ...